123 related articles for article (PubMed ID: 15545862)
1. Controversies in palivizumab use.
Stevens TP; Hall CB
Pediatr Infect Dis J; 2004 Nov; 23(11):1051-2. PubMed ID: 15545862
[No Abstract] [Full Text] [Related]
2. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
3. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
Meissner HC; Rennels MB; Pickering LK; Hall CB
Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
[No Abstract] [Full Text] [Related]
4. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
[TBL] [Abstract][Full Text] [Related]
7. [Indications and prescription modalities of palivizumab in neonates].
Guillois B
Arch Pediatr; 2007 Sep; 14 Suppl 1():S16-23. PubMed ID: 17939952
[TBL] [Abstract][Full Text] [Related]
8. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
10. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities.
Mohan AK; Braun MM; Ellenberg S; Hedje J; Coté TR
Pediatr Infect Dis J; 2004 Apr; 23(4):342-5. PubMed ID: 15071290
[TBL] [Abstract][Full Text] [Related]
11. Comments on palivizumab (Synagis).
Moler FW; Brown RW; Faix RG; Gilsdorf JR
Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
[No Abstract] [Full Text] [Related]
12. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Carbonell-Estrany X; Simões EA; Dagan R; Hall CB; Harris B; Hultquist M; Connor EM; Losonsky GA;
Pediatrics; 2010 Jan; 125(1):e35-51. PubMed ID: 20008423
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost-benefit evaluation in the Finistère Department].
Jacquemot L; Catelin C; Dobrzynski M; de Parscau L; Sizun J
Arch Pediatr; 2002 Feb; 9(2):219-21. PubMed ID: 11915507
[No Abstract] [Full Text] [Related]
14. Administration of palivizumab: a medical provider's perspective.
Helm EA; Cummings GE; Keane V; King JC
Clin Pediatr (Phila); 2003; 42(9):821-6. PubMed ID: 14686554
[No Abstract] [Full Text] [Related]
15. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
16. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
17. Optimum dosage regimen of palivizumab?
Zaaijer HL; Vandenbroucke-Grauls CM; Franssen EJ
Ther Drug Monit; 2002 Jun; 24(3):444-5. PubMed ID: 12021640
[TBL] [Abstract][Full Text] [Related]
18. Palivizumab for preterm infants. Is it worth it?
Embleton ND; Harkensee C; Mckean MC
Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
[TBL] [Abstract][Full Text] [Related]
19. Factors impacting compliance with palivizumab prophylaxis.
Pignotti MS; Indolfi G; Donzelli G
Pediatr Infect Dis J; 2004 Feb; 23(2):186-7. PubMed ID: 14872196
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
